UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000031870
Receipt number R000036392
Scientific Title The effect of supplement containing lutein on macular pigment optical density and visual performance
Date of disclosure of the study information 2018/03/23
Last modified on 2021/04/13 17:19:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of supplement containing lutein on macular pigment optical density and visual performance

Acronym

The effect of lutein supplement

Scientific Title

The effect of supplement containing lutein on macular pigment optical density and visual performance

Scientific Title:Acronym

The effect of lutein supplement

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficiency of supplement containing lutein on the macular pigment optical density and visual functions

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Macular pigment optical density (at 4,8,12,16 weeks after administration)

Key secondary outcomes

visual acuity
contrast sensitivity
glare sensitivity
skin carotenoid levels
skin AGEs levels


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

ngestion of supplementary drug containing lutein (16 weeks).

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

60 years-old >=

Gender

Male and Female

Key inclusion criteria

1.Healthy subjects aged 30 to 60 years-old
2. Macular pigment optical density of 0.64 or less in the measurement with Macular Metrics (Macular Metrics Inc.) at 0.5 eccentricity

Key exclusion criteria

1) Subjects with serious eye diseases
2) Visual acuity of less than 0.8
3) Myopia of -6.0 D and more
4) Subjects who have a gastrointestinal disorders such as malabsorption syndrome and history of gastrectomy causing absorption deficiency
5) Subjects who have under treatment of diabetes mellitus
6) Presence of cataract of a severity sufficient to affect the measurement of macular pigment
7) Pupil size less than 6.5 mm
8) Use of lutein and zeaxanthin supplements
9) Subjects who have an allergic to lutein, zeaxanthin or test food
10) Subjects who are in pregnancy, or lactation, or who planning to become pregnant or lactating during
11) Any candidates considered to be unsuitable for enrollment in the opinion of physician-in-charge

Target sample size

16


Research contact person

Name of lead principal investigator

1st name Akira
Middle name
Last name Obana

Organization

Seirei Hamamatsu General Hospital

Division name

Department of Ophthalmology

Zip code

430-8558

Address

2-12-12 Sumiyoshi, Naka-ku, Hamamatsu City, Shizuoka 430-8558, Japan

TEL

053-474-2222

Email

obana@sis.seirei.or.jp


Public contact

Name of contact person

1st name MItuo
Middle name
Last name Kimata

Organization

Seirei Hamamatsu General Hospital

Division name

Clinical research management center

Zip code

430-8558

Address

2-12-12 Sumiyoshi, Naka-ku, Hamamatsu City, Shizuoka 430-8558, Japan

TEL

053-474-1264

Homepage URL


Email

m-kimata@sis.seirei.or.jp


Sponsor or person

Institute

Deaprtment of Ophthalmology, Seirei Hamamatsu General Hospital

Institute

Department

Personal name



Funding Source

Organization

WAKAMOTO PHARMACEUTICAL Co,,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Seirei Hamamatsu General Hospital

Address

2-12-12 Sumiyoshi, Naka-ku, Hamamatsu City, Shizuoka 430-8558, Japan

Tel

053-474-2222

Email

hmchiken@sis.seirei.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

聖隷浜松病院眼科(静岡県) Department of Ophthalmology, Seirei Hamamatsu General Hospital


Other administrative information

Date of disclosure of the study information

2018 Year 03 Month 23 Day


Related information

URL releasing protocol

DOI: 10.1038/s41598-020-66962-2

Publication of results

Published


Result

URL related to results and publications

DOI: 10.1038/s41598-020-66962-2

Number of participants that the trial has enrolled

16

Results

Total volume of macular pigment optical density (MPOD) within 9 degrees eccentricity significantly increased by week 8 and continued to increase until week 16 (p < 0.0001, two-way factorial ANOVA). Skin carotenoid levels increased significantly by week 4 and continued to increase until week 16 (p < 0.0001, two-way factorial ANOVA). All subjects completed the study without any serious adverse events.

Results date posted

2021 Year 04 Month 13 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Subjects were 16 Japanese, age 26-57 years.

Participant flow

Subjects took a supplement containing 20 mg/day of lutein, 4 mg/day of zeaxanthin, and other antioxidants (vitamin C, vitamin E, zinc, copper) for 16 weeks.

Adverse events

None

Outcome measures

Macular pigment optical density, Skin carotenoid optical density

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 03 Month 14 Day

Date of IRB

2018 Year 03 Month 22 Day

Anticipated trial start date

2018 Year 03 Month 26 Day

Last follow-up date

2018 Year 12 Month 20 Day

Date of closure to data entry

2019 Year 07 Month 10 Day

Date trial data considered complete

2019 Year 07 Month 19 Day

Date analysis concluded

2019 Year 10 Month 01 Day


Other

Other related information



Management information

Registered date

2018 Year 03 Month 23 Day

Last modified on

2021 Year 04 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036392


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name